EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective
Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.616
https://www.valueinhealthjournal.com/article/S1098-3015(24)00731-9/fulltext
Section Title :
Section Order :
10089
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00731-9&doi=10.1016/j.jval.2024.03.616